Tumores Urológicos
Estudo de coorte | Metade dos homens com câncer de próstata de baixo risco passaram da vigilância para o tratamento em poucos anos.
30 Ago, 2021 | 11:41hEstudo original: Factors Associated With Discontinuation of Active Surveillance among Men With Low-Risk Prostate Cancer: A Population-Based Study – Journal of Urology
Estudo randomizado | Novo teste sanguíneo podem melhorar o rastreamento do câncer de próstata.
17 Ago, 2021 | 11:22hProstate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comunicado de imprensa: New blood test improves prostate cancer screening – Karolinska Institutet
Conteúdo relacionado: RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.
Comentário no Twitter
Online first: #Prostatecancer #screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial #pcsm https://t.co/bijoJk8RbK pic.twitter.com/ENWEjqG3Kr
— The Lancet Oncology (@TheLancetOncol) August 13, 2021
Estudo | Muitos pacientes com pequenos tumores renais podem ser tratados com segurança por meio de vigilância ativa.
2 Ago, 2021 | 18:50hCommentary: More Data Support Active Surveillance for Small Renal Masses — Most patients avoided surgery with no metastasis, better focus on aggressive disease – MedPage Today (necessário cadastro gratuito)
Estudo randomizado | Ressonância magnética reduz à metade os casos de “overdiagnosis” no rastreamento do câncer de próstata.
9 Jul, 2021 | 15:51hMRI-Targeted or Standard Biopsy in Prostate Cancer Screening – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: MRI can cut overdiagnoses in prostate-cancer screening by half – Karolinska Institutet
Artigos relacionados: RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer E Meta-Analysis: Negative Predictive Value of MRI in the Detection of Clinically Significant Prostate Cancer E Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis E Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management E Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer E Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer E Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy E Research: Biparametric MRI (simpler, faster) May Be Used to Exclude Aggressive Disease and Avoid Unnecessary Biopsies in Men with Clinical Suspicion of Prostate Cancer E Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis E Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer
Estudo randomizado | Lutétio-177-PSMA-617 para metástase de câncer de próstata resistente à castração.
24 Jun, 2021 | 10:50hLutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Estudo randomizado: Nivolumabe adjuvante vs. placebo no carcinoma urotelial invasivo muscular.
3 Jun, 2021 | 09:52hDiretriz AUA | Massa renal e câncer renal localizado: avaliação, tratamento e seguimento.
2 Jun, 2021 | 10:16hComentário: AUA updates guideline on renal masses and localized renal cancer – Urology Times